GDF-11 — The Rejuvenating Circulating Factor
Growth Differentiation Factor 11 (GDF-11) is a circulating protein belonging to the TGF-β superfamily, initially identified as a potential systemic rejuvenating factor in heterochronic parabiosis experiments. While its role in reversing age-related cardiac hypertrophy and skeletal muscle dysfunction in mice sparked significant interest, its therapeutic potential and exact mechanisms in human aging remain highly controversial.
Mechanism of Action
GDF-11 signals primarily through the TGF-β/Smad pathway, binding to activin type II receptors (ActRIIA/B) and phosphorylating Smad2/3 to regulate gene expression. In preclinical models, it has been proposed to reverse age-related cardiac hypertrophy, enhance neurogenesis, and improve skeletal muscle regeneration. However, conflicting studies suggest that GDF-11 levels may actually increase with age and that high levels could inhibit skeletal muscle regeneration, indicating a complex, context-dependent role in tissue homeostasis and aging.
Human Trial Evidence
No published human longevity trials. Animal/in-vitro evidence only.
Dosing Protocol
Unestablished in humans. Experimental animal models typically use recombinant GDF-11 via daily intraperitoneal injections, but no safe or effective human dosing protocol exists.
Safety & Contraindications
Unknown in humans. Given its role in the TGF-β pathway, potential risks include off-target effects on muscle wasting (cachexia), fibrosis, and paradoxical acceleration of aging phenotypes depending on the dose and context. It should be strictly avoided outside of controlled research settings.